You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Details for Patent: 10,918,608


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,918,608
Title:Use of cannabidiol in the treatment of epilepsy
Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Inventor(s): Guy; Geoffrey (Cambridge, GB), Wright; Stephen (Cambridge, GB), Thiele; Elizabeth (Boston, MA)
Assignee: GW Research Limited (Cambridge, GB)
Application Number:14/881,954
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,918,608: A Comprehensive Analysis

Introduction

Patents are a crucial component of intellectual property law, providing inventors and companies with exclusive rights to their innovations. The recent changes in the landscape of design patent obviousness, as seen in the LKQ Corp. v. GM Global Tech Operations decision, highlight the importance of staying updated on patent law and its implications. Here, we will delve into the specifics of United States Patent 10,918,608, examining its scope, claims, and the broader patent landscape.

Background on Patent 10,918,608

To analyze the scope and claims of a specific patent, it is essential to start with the patent document itself. United States Patent 10,918,608 would typically include a detailed description of the invention, drawings, and claims that define the subject matter of the patent.

Patent Description and Drawings

The patent description provides a detailed explanation of the invention, including its components, functionality, and any variations or embodiments. This section is crucial for understanding the scope of the invention and how it differs from prior art. The drawings accompanying the patent further illustrate the invention, helping to clarify any complex aspects described in the text[2].

Patent Claims

The claims section is the most critical part of a patent, as it defines the legal boundaries of the invention. Claims must be clear, concise, and particularly point out and distinctly claim the subject matter of the invention. This requirement is mandated by 35 USC 112(b) to ensure that the public and other inventors understand what is protected by the patent[5].

Analyzing the Claims

Claim Structure

Patent claims are typically structured in a hierarchical manner, with independent claims standing alone and dependent claims referring back to one or more previous claims. Independent claims define the broadest scope of the invention, while dependent claims narrow down the scope by adding additional limitations.

Claim Language

The language used in claims is critical. It must be precise enough to provide clear notice of what is claimed but also flexible enough to cover variations of the invention. Subjective terms can sometimes be necessary, but they must be supported by numerous and meaningful examples to avoid being deemed indefinite[5].

Design Patent Obviousness: The LKQ Corp. v. GM Global Tech Operations Decision

The recent LKQ Corp. v. GM Global Tech Operations decision by the Federal Circuit has significant implications for design patents. Here’s how it affects the analysis of Patent 10,918,608:

The Rosen-Durling Test

Previously, the Rosen-Durling test was used to determine the obviousness of design patents. This test required that there be an earlier design with "basically the same" visual impression as the patented design, and that it would have been obvious to modify the earlier design to arrive at the claimed design using related designs[1].

New Flexibility in Obviousness Analysis

The Federal Circuit has now discarded the Rosen-Durling test, deeming it "improperly rigid." Instead, the court has adopted a more flexible approach, similar to that used for utility patents, which is based on Supreme Court precedent such as KSR v. Teleflex. This new approach requires a more comprehensive assessment of the prior art from the perspective of an ordinary designer[1].

Impact on Patent 10,918,608

Increased Uncertainty

The elimination of the Rosen-Durling test introduces greater uncertainty for design patent owners and applicants. Without a clear framework for determining obviousness, there is a higher likelihood that competitors will challenge the validity of existing design patents, and examiners may reject design applications more frequently[1].

Strategic Considerations

To mitigate this uncertainty, patent applicants and owners should consider pursuing multiple embodiments of varying scope for each claimed design. This strategy increases the likelihood that at least one embodiment will be considered nonobvious under the new analysis framework[1].

Patent Prosecution Process

The prosecution process for Patent 10,918,608 would have involved several key steps:

Filing the Application

The applicant would have filed a patent application with the USPTO, including a written description of the invention, drawings, and claims[2].

Examination by the USPTO

The USPTO Examiner would have conducted a prior art search and evaluated the application for substantive compliance with Title 35 of the United States Code. Any rejections based on prior art would have been communicated to the applicant in an Office Action[2].

Negotiations and Amendments

The applicant would have responded to any rejections by amending the claims or presenting technical arguments to overcome the rejections. This process could involve multiple rounds of negotiations between the applicant and the Examiner[2].

Searching and Analyzing Prior Art

Tools and Resources

To analyze the prior art relevant to Patent 10,918,608, several tools and resources are available:

USPTO Public Search Facility

The USPTO Public Search Facility in Alexandria, VA, provides access to patent and trademark information in various formats. Trained staff can assist in conducting searches[4].

Patent and Trademark Resource Centers (PTRCs)

Local PTRCs maintain search resources and offer training in patent search techniques, which can be invaluable for identifying relevant prior art[4].

Common Citation Document (CCD)

The CCD application consolidates prior art cited by participating IP offices, allowing for a comprehensive view of the prior art landscape for a given invention[4].

Key Takeaways

  • Claims Analysis: The claims of Patent 10,918,608 must be carefully analyzed to understand the scope of the invention and how it stands against the new obviousness standards.
  • Design Patent Obviousness: The LKQ Corp. v. GM Global Tech Operations decision introduces a more flexible and comprehensive approach to determining obviousness in design patents.
  • Strategic Considerations: Pursuing multiple embodiments of varying scope can help mitigate the uncertainty introduced by the new obviousness analysis framework.
  • Patent Prosecution: Understanding the patent prosecution process is crucial for navigating the complexities of patent law and ensuring that the patent application is thoroughly vetted.

FAQs

What is the significance of the LKQ Corp. v. GM Global Tech Operations decision for design patents?

The decision eliminates the "improperly rigid" Rosen-Durling test for design patent obviousness, adopting a more flexible approach similar to that used for utility patents, which may make it easier for competitors to challenge design patents and for examiners to reject design applications.

How does the new obviousness analysis framework affect patent applicants and owners?

The new framework introduces greater uncertainty, making it more likely for competitors to challenge the validity of existing design patents and for examiners to reject design applications. To mitigate this, applicants should consider pursuing multiple embodiments of varying scope.

What tools and resources are available for searching and analyzing prior art?

Tools include the USPTO Public Search Facility, Patent and Trademark Resource Centers (PTRCs), and the Common Citation Document (CCD) application, which help in identifying and analyzing relevant prior art.

How should patent claims be drafted to avoid being deemed indefinite?

Claims should be clear and concise, particularly pointing out and distinctly claiming the subject matter of the invention. Subjective terms must be supported by numerous and meaningful examples to avoid being deemed indefinite.

What is the role of the USPTO Examiner in the patent prosecution process?

The USPTO Examiner conducts a prior art search, evaluates the application for substantive compliance, and communicates any rejections or issues to the applicant in an Office Action, starting a process of negotiations and potential amendments.

Sources

  1. Full Federal Circuit Eliminates “Improperly Rigid” Tests for Design Patent Obviousness. Ballard Spahr.
  2. US Patent Prosecution - Hayes Soloway, P.C.. Hayes Soloway.
  3. Patent and patent application Claims data (Stata (.dta) and MS Excel ...). USPTO.
  4. Search for patents - USPTO. USPTO.
  5. Practical Advice for Drafting Patents with Subjective Claims Terms. Buchanan Ingersoll & Rooney PC.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,918,608

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Jazz Pharms Res EPIDIOLEX cannabidiol SOLUTION;ORAL 210365-001 Sep 28, 2018 RX Yes Yes ⤷  Subscribe ⤷  Subscribe USE FOR THE TREATMENT OF GENERALIZED SEIZURES OR FOCAL SEIZURES WITH IMPAIRMENT IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX ⤷  Subscribe
Jazz Pharms Res EPIDIOLEX cannabidiol SOLUTION;ORAL 210365-001 Sep 28, 2018 RX Yes Yes ⤷  Subscribe ⤷  Subscribe USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX ⤷  Subscribe
Jazz Pharms Res EPIDIOLEX cannabidiol SOLUTION;ORAL 210365-001 Sep 28, 2018 RX Yes Yes ⤷  Subscribe ⤷  Subscribe USE FOR REDUCING SEIZURE FREQUENCY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,918,608

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom1418170.5Oct 14, 2014

International Family Members for US Patent 10,918,608

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015332208 ⤷  Subscribe
Australia 2021201510 ⤷  Subscribe
Brazil 112017007767 ⤷  Subscribe
Canada 2963202 ⤷  Subscribe
Cyprus 1123459 ⤷  Subscribe
Denmark 3206715 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.